Low willingness to vaccinate against herpes zoster in a Chinese metropolis

References

• Adams EN, Parnapy S, Bautista P. Herpes zoster and vaccination: a clinical review. Am J Health Syst Pharm. 2010;67:724–27. doi:10.2146/ajhp090118.
   PubMed Web of Science ®Google Scholar
• Koshy E, Mengting L, Kumar H, Jianbo W. Epidemiology, treatment and prevention of herpes zoster: a comprehensive review. Indian J Dermatol Venereol Leprol. 2018;84:251–62. doi:10.4103/ijdvl.IJDVL_1021_16.
   PubMed Web of Science ®Google Scholar
• Saguil A, Kane S, Mercado M, Lauters R. Herpes Zoster and Postherpetic Neuralgia: prevention and Management. Am Fam Physician. 2017;96:656–63.
   PubMed Web of Science ®Google Scholar
• Thompson RR, Kong CL, Porco TC, Kim E, Ebert CD, Acharya NR. Herpes Zoster and post-herpetic Neuralgia: changing incidence rates from 1994 to 2018 in the United States. Clin Infect Dis. 2020;ciaa1185. doi:10.1093/cid/ciaa1185.
   Web of Science ®Google Scholar
• Pentikis HS, Matson M, Atiee G, Boehlecke B, Hutchins JT, Patti JM, Henson GW, Morris A. Pharmacokinetics and safety of FV-100, a novel oral anti-herpes zoster nucleoside analogue, administered in single and multiple doses to healthy young adult and elderly adult volunteers. Antimicrob Agents Chemother. 2011;55:2847–54. doi:10.1128/AAC.01446-10.
   PubMed Web of Science ®Google Scholar
• Kawai K, Gebremeskel BG, Acosta CJ. Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open. 2014;4:e004833. doi:10.1136/bmjopen-2014-004833.
   PubMed Web of Science ®Google Scholar
• Hata A, Kuniyoshi M, Ohkusa Y. Risk of Herpes zoster in patients with underlying diseases: a retrospective hospital-based cohort study. Infection. 2011;39:537–44. doi:10.1007/s15010-011-0162-0.
   PubMed Web of Science ®Google Scholar
• Heymann AD, Chodick G, Karpati T, Kamer L, Kremer E, Green MS, Kokia E, Shalev V. Diabetes as a risk factor for herpes zoster infection: results of a population-based study in Israel. Infection. 2008;36:226–30. doi:10.1007/s15010-007-6347-x.
   PubMed Web of Science ®Google Scholar
• Imafuku S, Matsuki T, Mizukami A, Goto Y, de Souza S, Jégou C, Bianco V, Rosillon D, Ito C, Curran D, et al. Burden of Herpes Zoster in the Japanese population with immunocompromised/chronic disease conditions: results from a cohort study claims database from 2005-2014. Dermatol Ther (Heidelb). 2019;9:117–33. doi:10.1007/s13555-018-0268-8.
   PubMed Web of Science ®Google Scholar
• Willis ED, Woodward M, Brown E, Popmihajlov Z, Saddier P, Annunziato PW, Halsey NA, Gershon AA. Herpes zoster vaccine live: a 10 year review of post-marketing safety experience. Vaccine. 2017;35:7231–39. doi:10.1016/j.vaccine.2017.11.013.
   PubMed Web of Science ®Google Scholar
• Syed YY. Recombinant Zoster Vaccine (Shingrix®): a review in Herpes Zoster. Drugs Aging. 2018;35:1031–40. doi:10.1007/s40266-018-0603-x.
   PubMed Web of Science ®Google Scholar
• Zhang D, Johnson K, Newransky C, Acosta CJ. Herpes zoster vaccine coverage in older adults in the U.S., 2007-2013. Am J Prev Med. 2017 Jan;52(1):e17–e23. Epub 2016 Oct 26. doi:10.1016/j.amepre.2016.08.029.
   PubMed Web of Science ®Google Scholar
• Liu XC, Simmonds KA, Russell ML, Svenson LW. Herpes zoster vaccine (HZV): utilization and coverage 2009-2013, Alberta, Canada. BMC Public Health. 2014;14:1098. doi:10.1186/1471-2458-14-1098.
   PubMed Web of Science ®Google Scholar
• Lam AC, Chan MY, Chou HY, Ho SY, Li HL, Lo CY, Shek KF, To SY, Yam KK, Yeung I. A cross-sectional study of the knowledge, attitude, and practice of patients aged 50 years or above towards herpes zoster in an out-patient setting. Hong Kong Med J. 2017;23:365–73. doi:10.12809/hkmj165043.
   PubMed Web of Science ®Google Scholar
• Akel KB, Masters NB, Shih SF, Lu Y, Wagner AL. Modification of a vaccine hesitancy scale for use in adult vaccinations in the United States and China. Hum Vaccin Immunother. 2021;1–8. doi:10.1080/21645515.2021.1884476.
   Google Scholar
• Qiu J, Sun X, Hu J, Huang Z, Guo X, Liang X. Willingness to receive herpes zoster vaccine and factors influencing willingness among ≥50-year-old adults of Shanghai in May-June 2020. Chin J Vaccines Immunization. 2020;27:307–310, 327.
   Google Scholar
• Yin D, Van Oorschot D, Jiang N, Marijam A, Saha D, Wu Z, Tang H, Diaz-Decaro J, Watson P, Xie X, et al. A systematic literature review to assess the burden of herpes zoster disease in China. Expert Rev Anti Infect Ther. 2021;19:165–79. doi:10.1080/14787210.2020.1792290.
   PubMed Web of Science ®Google Scholar
• Papagiannis D, Rachiotis G, Mariolis A, Zafiriou E, Gourgoulianis KI. Vaccination coverage of the elderly in greece: a cross-sectional nationwide study. Can J Infect Dis Med Microbiol. 2020;2020:5459793. doi:10.1155/2020/5459793.
   PubMed Web of Science ®Google Scholar
• Williams WW, Lu PJ, O’Halloran A, Kim DK, Grohskopf LA, Pilishvili T, Skoff TH, Nelson NP, Harpaz R, Markowitz LE, et al. Surveillance of vaccination coverage among adult populations - United States, 2015. MMWR Surveill Summ. 2017;66:1–28. doi:10.15585/mmwr.ss6611a1.
   PubMed Web of Science ®Google Scholar
• Tricco AC, Zarin W, Cardoso R, Veroniki AA, Khan PA, Nincic V, Ghassemi M, Warren R, Sharpe JP, Page AV, et al. Efficacy, effectiveness, and safety of herpes zoster vaccines in adults aged 50 and older: systematic review and network meta-analysis. BMJ. 2018;363:k4029. doi:10.1136/bmj.k4029.
   PubMedGoogle Scholar